Literature DB >> 26245678

Effect of bacterial and host factors on Helicobacter pylori eradication therapy.

Takahiro Uotani1,2, Muhammad Miftahussurur1,3, Yoshio Yamaoka1,2.   

Abstract

INTRODUCTION: A clearer understanding of the factors affecting the cure rate of Helicobacter pylori infection might lead to the development of novel prevention strategies and therapeutic targets. AREAS COVERED: This review covers two important issues that affect the eradication of H. pylori: bacterial and host factors. Several virulence factors have been shown to be predictors for gastroduodenal diseases. Successful treatment of H. pylori infection also depends on host genetic factors such as CYP2C19 and IL-1B. The latest evidence on host genetic factors is discussed. EXPERT OPINION: The authors identify three main targets for achieving effective eradication therapy. The first therapeutic target is to identify counter measures for antibiotic-resistant H. pylori strains. Thus, antibiotic susceptibility should be checked in all patients, ideally, before the start of eradication treatment. The second therapeutic target is the inhibition of acid suppression. Maintaining a high intragastric pH for 24 h increases the effectiveness of some antibiotics and the eradication effects for H. pylori. The third therapeutic target is to identify high-risk groups; the CYP2C19 and IL-1B polymorphisms are candidates for significant risk factors. A personalized medical approach will likely increase the cure rate of H. pylori infection.

Entities:  

Keywords:  Helicobacter pylori; antibiotic resistance; cytochrome P450 2C19; interleukin 1B; virulence factors

Mesh:

Substances:

Year:  2015        PMID: 26245678      PMCID: PMC5332544          DOI: 10.1517/14728222.2015.1073261

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  94 in total

1.  Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea.

Authors:  Nayoung Kim; Jung Mogg Kim; Chung Hyun Kim; Young Soo Park; Dong Ho Lee; Joo Sung Kim; Hyun Chae Jung; In Sung Song
Journal:  J Clin Gastroenterol       Date:  2006-09       Impact factor: 3.062

2.  Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study.

Authors:  Rocco Maurizio Zagari; Gabriele Bianchi-Porro; Roberto Fiocca; Giovanni Gasbarrini; Enrico Roda; Franco Bazzoli
Journal:  Gut       Date:  2006-10-06       Impact factor: 23.059

3.  TNF and LTA gene polymorphisms reveal different risk in gastric and duodenal ulcer patients.

Authors:  A Lanas; M A García-González; S Santolaria; J B Crusius; M T Serrano; R Benito; A S Peña
Journal:  Genes Immun       Date:  2001-12       Impact factor: 2.676

4.  Secular trends in Helicobacter pylori seroprevalence in adults in the United States: evidence for sustained race/ethnic disparities.

Authors:  Yonatan H Grad; Marc Lipsitch; Allison E Aiello
Journal:  Am J Epidemiol       Date:  2011-11-15       Impact factor: 4.897

5.  Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States.

Authors:  M S Osato; R Reddy; S G Reddy; R L Penland; H M Malaty; D Y Graham
Journal:  Arch Intern Med       Date:  2001-05-14

6.  The association of dupA and Helicobacter pylori-related gastroduodenal diseases.

Authors:  N R Hussein
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-04-25       Impact factor: 3.267

Review 7.  Helicobacter pylori VacA, a paradigm for toxin multifunctionality.

Authors:  Timothy L Cover; Steven R Blanke
Journal:  Nat Rev Microbiol       Date:  2005-04       Impact factor: 60.633

8.  Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy.

Authors:  Mitsushige Sugimoto; Takahisa Furuta; Naohito Shirai; Chise Kodaira; Masafumi Nishino; Mutsuhiro Ikuma; Takashi Ishizaki; Akira Hishida
Journal:  Helicobacter       Date:  2007-08       Impact factor: 5.753

9.  Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation.

Authors:  A G Wilson; J A Symons; T L McDowell; H O McDevitt; G W Duff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

10.  Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.

Authors:  Mitsushige Sugimoto; Takahiro Uotani; Shu Sahara; Hitomi Ichikawa; Mihoko Yamade; Ken Sugimoto; Takahisa Furuta
Journal:  Helicobacter       Date:  2014-04-01       Impact factor: 5.753

View more
  8 in total

1.  The association between vacA or cagA status and eradication outcome of Helicobacter pylori infection: A meta-analysis.

Authors:  Dan Wang; Qiuping Li; Yuehua Gong; Yuan Yuan
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

2.  The Bifunctional Enzyme SpoT Is Involved in the Clarithromycin Tolerance of Helicobacter pylori by Upregulating the Transporters HP0939, HP1017, HP0497, and HP0471.

Authors:  Xiwen Geng; Wen Li; Zhenghong Chen; Sizhe Gao; Wei Hong; Xiaoran Ge; Guihua Hou; Zhekai Hu; Yabin Zhou; Beini Zeng; Wenjuan Li; Jihui Jia; Yundong Sun
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

3.  Can bacterial virulence factors predict antibiotic resistant Helicobacter pylori infection?

Authors:  Denise E Brennan; Colin Dowd; Colm O'Morain; Deirdre McNamara; Sinéad M Smith
Journal:  World J Gastroenterol       Date:  2018-03-07       Impact factor: 5.742

4.  The antibiotic resistance of Helicobacter pylori to five antibiotics and influencing factors in an area of China with a high risk of gastric cancer.

Authors:  Dan Wang; Qianqian Guo; Yuan Yuan; Yuehua Gong
Journal:  BMC Microbiol       Date:  2019-07-04       Impact factor: 3.605

5.  Clarithromycin-Susceptible But Virulent Helicobacter pylori Strains Infecting Iranian Patients' Stomachs.

Authors:  Shadiyeh Khani; Amin Talebi Bezmin Abadi; Ashraf Mohabati Mobarez
Journal:  Infect Drug Resist       Date:  2019-11-01       Impact factor: 4.003

6.  Helicobacter pylori Eradication Efficacy of Therapy Based on the Antimicrobial Susceptibility in Children with Gastritis and Peptic Ulcer in Mekong Delta, Vietnam.

Authors:  Loan T T Le; Tuan A Nguyen; Nghia A Nguyen; Yen T H Nguyen; Hai T B Nguyen; Liem T Nguyen; Mai T Vi; Thang Nguyen
Journal:  Children (Basel)       Date:  2022-07-08

7.  Involvement of Helicobacter pylori in Preoperative Gastric Findings on a Bariatric Population.

Authors:  Soledad García-Gómez-Heras; María Jesús Fernández-Aceñero; Gilberto González; María de Lourdes Bolaños-Muñoz; Raquel Franco-Rodríguez; Julio Paredes-González; Jaime Ruiz-Tovar
Journal:  Int J Environ Res Public Health       Date:  2022-07-26       Impact factor: 4.614

Review 8.  Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets.

Authors:  Paula Roszczenko-Jasińska; Marta Ilona Wojtyś; Elżbieta K Jagusztyn-Krynicka
Journal:  Appl Microbiol Biotechnol       Date:  2020-10-14       Impact factor: 4.813

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.